VistaGen, Centre for Commercialization of Regenerative Medicine (CCRM) gene/cell therapy news

VistaGen joined the not-for-profit CCRM, which offers its members proprietary access to licensing opportunities, academic rates on fee-for-service contracts at CCRM and opportunities to participate in collaborative projects. The public-private consortium is funded by the Canadian government, six Ontario-based institutional partners and over 20 companies involved in regenerative medicine, including Pfizer Inc. (NYSE:PFE, New York, N.Y.) and Lonza Group Ltd. (SIX:LONN, Basel, Switzerland). VistaGen said the annual fee for membership is $25,000, but that CCRM makes accommodations for emerging companies. The biotech declined to disclose details. ...